白蛋白结合型紫杉醇与多西紫杉醇在乳腺癌新辅助化疗中的疗效分析  

Clinical Effect of Chemotherapy by Albumin-bound Paclitaxel or Docetaxel in the Neoadjuvant Treatment of Breast Cancer Patients

作　　者：廖富毅[1] 杨劼[1] 潘瑞琳[1] 

机构地区：[1]广东省佛山市第一人民医院胸外乳腺外科,广东省佛山市528000

出　　处：《中国肿瘤临床》2011年第13期801-803,807,共4页Chinese Journal of Clinical Oncology

摘　　要：目的:比较白蛋白结合型紫杉醇与多西紫杉醇在乳腺癌新辅助化疗中的效果。方法:56例乳腺癌患者均采用TEC方案行新辅助化疗;其中26例应用白蛋白结合型紫杉醇为研究组,另外30例应用多西紫杉醇为对照组;完成4疗程后进行手术并评价疗效。结果:研究组与对照组的pCR率分别为38.5%和10%(P<0.05),总有效率(CR+PR)分别为88.5%和73.3%(P>0.05)。结论:白蛋白结合型紫杉醇在乳腺癌新辅助化疗中的病理完全缓解率显著高于多西紫杉醇;总有效率可能高于多西紫杉醇。Objective： To compare the clinical effect of chemotherapy using the protein-binding Abraxane with that using Doeetaxel in the neoadjuvant therapy of breast cancer. Methods： Neoadjuvant chemotherapy with TEC regimen was administered in 56 patients. Twenty six patients were treated with Abraxane （study group ）, whereas 30 patients were treated with Docetaxel （ control group ）. Surgery was conducted after 4 courses of the regimen, and the therapeutic effect was appraised. Results： The pathological complete remission （ pCR ） rate was 38.5% and 10% in the study and control groups, respectively （ P 〈 0.05 ）. The total effective rate （ clinical complete remission plus clinical partial response ） was 88.5% and 73.3% in the Abraxane and Docetaxel groups, respectively （ P 〉 0.05 ）. Conclusion： The pCR rate is higher in breast cancer patients treated with albumin-binding Abraxane compared with those who were administered with Docetaxel. The total effective rate may also be higher in the study group than in the control group.

关 键 词：乳腺肿瘤 新辅助化疗 白蛋白结合型紫杉醇 多西紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]